Does basal type breast cancer arise from oncogenic transformation of a basal cell type? In this issue of Cell Stem Cell, Molyneux et al. (2010) investigate the provenance of the basal-type BRCA1 breast carcinoma and come up with unanticipated results.
Breast cancer is a diverse disease that can be categorized into at least six clinically relevant subtypes based upon molecular gene signatures. The subtypes fit into the broader groupings of either ''basal'' or ''luminal'' types because of their molecular similarity to the basal or luminal cells of the normal mammary gland. Thus, basal-type breast cancers express high levels of basal cell markers (cytokeratins 5/6, 14, and 17), whereas luminal-type breast cancers are defined by high expression of luminal cell markers (estrogen receptor alpha, cytokeratins 8/18, and GATA3-binding protein) (Sorlie et al., 2003) . Such parallels suggest that the biology of the target cell of oncogenic transformation is echoed in the disease that ensues. Put simply, basal-type breast cancers would seem to arise from transformed mammary basal progenitor cells and luminal-type breast cancers from transformed luminal progenitor cells (Petersen and Polyak, 2010) .
BRCA1 is a tumor suppressor gene that is often mutated in the germ line, giving rise to greatly elevated risk of developing basal-type breast carcinoma. Previous work had proposed that BRCA1 is an important regulator of mammary stem cell fate and that breast tissues from women with germline BRCA1 mutations had an expansion of BRCA1 mutant mammary stem/progenitor cells (Liu et al., 2008 (Liu et al., 2007) . As such, BRCA1 mutant breast cancer was thought to arise from a basal progenitor/stem cell.
A recent flow of papers, however, call this notion into question. In this issue of Cell Stem Cell, Molyneux et al. (2010) took a novel approach to define the cell of origin for BRCA1 mutant breast cancer. They analyzed a conditional mouse model of BRCA1 deficiency, in which Cre recombinase-dependent deletion of exons encoding the C terminus of the BRCA1 protein combined with p53 heterozygosity lead to tumor formation. Pertinent to this model, Cre expression was driven by the Beta lactoglobulin (Blg) promoter and is therefore confined to a subpopulation of mammary epithelial cells. Importantly, the Blg-Cre Brca1 f/f p53 +/À transgenic mice developed mammary tumors that closely resembled human BRCA1 mutant breast cancer. Accordingly, identifying the phenotype of the Blg-positive cells in the mouse mammary gland should shed light on the cell of origin for BRCA1 basal-type breast carcinoma.
To that end, the authors used cellsurface antigen profiles to distinguish three different mammary epithelial populations. They demonstrated that Blg activity is most evident in a CD24 +/High Sca-1 À ER À cell population, thus defining a luminal ER À progenitor cell as the cell of origin for BRCA1 mutant basal-like tumors ( Figure 1 ). This novel work is at odds with the previous contention that BRCA1 mutant tumors arise from a mammary basal cell (Liu et al., 2007) . To further address these conflicting data, Molyneux et al. (2010) Perhaps the key to interpreting these novel findings lies in a degree of cellular plasticity that is thought to be largely confined to mammary stem cells. The current depiction of the conventional stem cell hierarchy suggests that stem cells can undergo asymmetric division to create nonstem daughters. Conversely, nonstem cells are portrayed as being unable to move back up the hierarchy and dedifferentiate into a stem cell state. However, if (as the authors suspect) nonstem cells did indeed have this ability, via either a normal cellular process or a consequence of genetic alterations (such as those associated with tumorigenesis), it is possible that luminal progenitor cells acquiring a BRCA1 mutation might undergo a degree of dedifferentiation, allowing them to revert to a bipotent progenitor or even an oligopotent stem cell state (both of which states exhibit basal characteristics). In this event, luminal progenitor cells would be able to give rise to carcinomas with a basal phenotype (via conversion to a bipotent progenitor or stem cell).
In accord with the idea presented by Molyneux et al., another group recently demonstrated that a basal cell might also be the cell of origin in a model of prostate cancer, a disease characterized by luminal cell expansion and the absence of basal cells (Goldstein et al., 2010) . These findings lend further support to the emerging theme that the histology of cancer does not always reflect the nature of the cell of origin. Identifying the target cells of transformation is key to understanding the pathogenesis of these common human tumors. Such information may also prove critical to developing more powerful diagnostic and prognostic tools than are currently available.
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À mutant basal-like breast carcinoma. It is also possible that luminal ER À progenitor cells can transdifferentiate into basal progenitor cells as part of a normal physiological process, either directly (depicted by arrow with a question mark) or first via dedifferentiation to a bipotent progenitor/stem cell.
